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The Effect of Vascular Endothelial Growth Factor on Angiogenesis.
An Experimental Study
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Objective: to evaluate the effects of exogenous vascular endothelial growth factor (VEGF) on angiogenesis in a rabbit
model of persistent hind limb ischaemia.
Materials and methods: ischaemia was induced in the hind limbs of 42 New Zealand white rabbits divided into six
groups, each of 7 animals. Group 1a and 1b received intramuscular injections of 1 and 2 mg VEGF/day, respectively,
into the ischaemic hind limb for 10 days beginning on postoperative 11th day, and group 1c received IM injections of
saline only. Group 2a and 2b received similar regimen of VEGF, but administered intra-arterially. Group 2c served as
controls. Perfusion of the ischaemic limb was evaluated by thigh blood pressure and thigh circumference at 10, 25 and
40 days following limb ischaemia in all animals and by digital subtraction angiography, perfusion scans, histological
examination of capillary density in 2 animals from each group.
Results: thigh pressure index and thigh circumference improved significantly in the VEGF treated animals (Groups 1a,
b and 2a,b). Collateral formation, as assessed by angiography, scintigraphy and by histological examination, indicated
marked formation of collaterals in the VEGF treated animals as compared with the controls. This was most pronounced
in groups receiving the highest dose of VEGF.
Conclusion: these data suggest that VEGF promotes angiogenesis, that the route of administration is unimportant, but
that a dose-response relationship is present in this experimental ischaemic hind limb model.
Key Words: Angiogenesis; Vascular endothelial growth factor.
Introduction by the Institute of Laboratory Animal Resources and
the “Guide for the Care and Use of Laboratory An-
imals” published by the National Institutes of HealthThe number of people suffering from lower-extremity
(NIH publication No. 85-23, revised 1985).ischaemia is increasing.1 Approximately 20% of
Forty-two adult New Zealand White rabbits (meanpatients with limb-threatening ischaemia have disease
weight 2.350 kg) were used in this study and dividedthat is so extensive that direct revascularisation cannot
into two groups: intramuscular (IM) (Group 1, n=21)be undertaken successfully.2–7
and intra-arterial (IA) (Group 2, n=21). Group 1 wasAngiogenesis describes the formation of new blood
divided into three subgroups as 1a, 1b and 1c (n=7vessels. Angiogenic stimulation may lead to angio-
in each subgroup). Group 2 was also divided into threegenesis in ischaemic tissue,8,9 and so provide an al-
subgroups as 2a, 2b and 2c (n=7 in each subgroup).ternative treatment for severe chronic limb ischaemia.
Division of animals as Group 1 and Group 2 wasVascular endothelial growth factor (VEGF) is a soluble
designed to determine if a method of administration-compound, has 165 amino acid residues, is able to
response relationship could be demonstrated forbind heparin and is commonly found in normal cells.
VEGF. The purpose of different doses of VEGF in both
Group 1 and Group 2 was to determine if a dose-
response relationship could be demonstrated forMaterials and Methods
VEGF. Anaesthesia was established by 40 mg/kg ke-
tamin IM together with 5 mg/kg xylazine. VenousAll procedures were done in conformity with the
route was achieved from the vena auricularies. Cardiac“Principles of Laboratory Animal Care” formulated rhythms were monitorised. Throughout the operation
heart rates were between 176–190 beats/min. A lon-∗ Please address all correspondence to: N. Becit, Atatu¨rk U¨niversitesi
loj. 8/7, Erzurum, Turkey. gitudinal incision was made in the right groin from
1078–5884/01/100310+07 $35.00/0  2001 Harcourt Publishers Ltd.
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Study parameters
Clinical assessment; superficial tissue necrosis in toes,
thigh circumference difference, thigh blood pressure, and
thigh pressure index
Those parameters were evaluated preoperatively and
at postoperative days 1, 10, 25, 40. After the hind limb
were shaved and cleaned, standard sphygmo-
manometer with a cuff of 2.5 cm width and Doppler
flow meter were used to measure thigh blood pressure
of the rabbits. Cuff was placed on the thigh. After the
Fig. 1. Tc99m macroaggregate radioisotopic perfusion scintigrams of two rabbits from Group 1c (control) (a) and Group 1b (2 mg VEGF)
(b) obtained at 40th day. Perfusion in the right hind limb in panel B is better than the right hind limb in panel B.
the inguinal ligament to the knee. With the aid of
surgery loop, the femoral artery was dissected, and
its branches, the profunda, the lateral circumflex, and
the superficial epigastric were exposed as completely
as possible. The proximal popliteal and saphenous
arteries were also dissected free.
With the help of a catheter placed from superficial
femoral artery, arterial blood pressure was monitorised
and recorded. Before ligation of external iliac artery,
thigh blood pressure of rabbits was between
76–90 mmHg. After ligation of external iliac artery,
thigh blood pressure of rabbits decreased to Doppler probe detected the pulse of the posterior tibial
17–20 mmHg. Ischaemia was induced in hind limb by artery in the lower calf, the cuff was inflated until a
ligation of the external iliac artery, the inferior epi- pressure that was 30 mmHg higher than the predicted
gastric artery, all the branches of the femoral artery, systolic pressure. The pressure of sphygmomanometer
and the proximal popliteal and sapheneal arteries. was reduced with a speed of 3 mmHg/s. The moment
Complete excision of common and superficial femoral at which the flow signals were heard was recorded as
arteries was performed. Throughout operation, systolic blood pressure. Thigh pressure index was
50±10 ml of 0.9% sodium chloride was infused to defined as the ratio of the right thigh to left thigh
each subject from vein auricularis anteriores. No hep- systolic blood pressure.
arin was used in all processes for avoiding endogen In addition, two rabbits from each group, which
VEGF production or activation. During the post- were selected randomly, were evaluated by angio-
operative seven days, prophylactic antibiotic (15 mg/ graphy, calf radioisotopic perfusion scan and histo-
kg/daily dose cefazolin Na, IM) was administered. logical examination on postoperative 40th days. Under
For analgesia, 400 /kg/daily dose of morphine was anaesthesia, the left common carotid artery was ex-
administered to the subjects for 10 days. An interval posed; a catheter was introduced into the exposed
of 10 days between surgery and VEGF administration artery and advanced to arcus aorta. Economical prob-
was left to allow improvement of endogen collateral lems were the major limiting factor that these in-
vessels and postoperative recovery of the rabbits. None vestigations could be performed only in 2 animals
of the animals died during the study period. from each group.
Treatment regiments in each group are given in
Figure 1. At postoperative 11th day, animals in Group
Calf radioisotopic perfusion scan2 were slept by giving 5 mg/kg hyaline and 40 mg/
Arterial perfusion was determined radioisotopicallykg ketamin. With incision carried out above the right
using 99mTc macroaggregates that measured 15–30 minguinal ligament, the proximal of external iliac artery
in diameter. The aggregates are designed to be so largewas dissected. Through external iliac artery, VEGF or
saline solution was administered. that they will be trapped in the capillary bed. Through
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the previously placed catheter, 2 mCi of 99mTc macro- from Group 1a, and one animal from Group 2a de-
veloped obvious muscle atrophy in their hind limbsaggregates in 2 ml saline was injected. After injection,
the limbs of the animals were scanned and counted and/or superficial tissue necrosis in distal toes. In
contrast, none of the animals from Group 1b and 2bon a gamma camera that was interfaced to a computer
system. The accumulated counts were stored on a manifested any clinical problems in the right hind
limb. When thigh pressure index determined at post-disk for later retrieval and analysis. At that time, the
radioactive counts from each calf were generated from operative 1st and 10th days were compared, there
was no statistically significant difference between thecorresponding regions of interest symmetrically, and
the ratio of the counts between the calves was cal- groups (0.26 in the Group 1a, 1b, 1c and 2c, 0.25 in
the Group 2a and 0.27 in the Group 2b) (p>0.05), andculated as an index of relative calf perfusion.
a serious ischaemia was obvious in all Groups. The
Angiography lower the value obtained, the greater the disparity in
Angiograms were performed by DSA to visualise the arterial perfusion of the two limbs. At postoperative
vasculature in both hind limbs simultaneously. 25th day, it was determined that there was statistically
Through the catheter, 30 ml of contrast agent by an significant difference between Groups 1a, 1b, 2a and
automatic injector was injected at a rate of 5 ml/s. 2b and Groups 1c and 2c with respect to the thigh
Satisfactory DSA imaginations were obtained in all blood pressures, the thigh pressure index (0.61 in the
animals. Vascularisation in the thigh was determined Group 1a, 0.71 in the Group 1b, 0.41 in the Group 1c,
from the angiograms and defined as the number of 0.60 in the Group 2a, 0.68 in the Group 2b and 0.42 in
collateral vessels extending along a vertically drawn the Group 2c), and the difference in thigh cir-
line that passed through the centre of the femur. cumference (p<0.01). The values obtained at 40th day
(0.68 in the Group 1a, 0.83 in the Group 1b, 0.47 in
Histological examination the Group 1c, 0.71 in the Group 2a, 0.81 in the Group
Muscle biopsy samples taken from adductor and semi- 2b and 0.48 in the Group 2c) were significantly higher
membranous muscles in ischaemic limb of the rabbits than those of 25th day (p<0.001) (Table 1).
were examined histologically for determination of When one compared Group 1a with Group 2a and
histological findings of capillary artery formation. The Group 1b with Group 2b, it was seen that there was no
muscle specimen was fixed in 10% buffered formalin, statistically significant difference regarding superficial
embedded in paraffin, and sectioned in 10 m cross tissue necrosis in toes, thigh circumference difference,
sections. Each section was stained with hematoxylin thigh blood pressure, and thigh pressure index
and eosin and was examined microscopically. The (p>0.05). On the other hand, when we compared Group
number of fibres and capillary in twenty different 1a with Group 1b, and Group 2a with Group 2b,
100 times magnified fields was determined in light statistically significant difference was detected
microscope as electron microscopy was not available. (p<0.001).
Capillary per muscle fibre ratio was calculated as Two rabbits from each group, which were selected
capillary numbers/muscle fibre numbers in mm2. randomly, were evaluated by angiography, calf radio-
isotopic perfusion scan and histological examination
Statistical analysis on postoperative 40th days.
All data were expressed as the median values. Com-
parison of the data based on all 7 animals in the 6 Calf radioisotopic perfusion scans (CRPR)
Groups was done with a computer statistical package The median calf perfusion ratios were 0.55 in Group 1a,
using non-parametric Mann–Whitney U-test to deter- 0.93 in Group 1b, 0.31 in Group 1c, 0.49 in Group 2a,
mine the effect of administration route and non-para- 0.90 in Group 2b and 0.31 in Group 2c (Table 2). Calf
metric Kruskal–Wallis test to determine the dose- radioisotopic perfusion ratios in Groups 1a, 1b, 2a and
response relationship. A p value less than 0.05 was 2b had better than Groups 1c and 2c. The Groups 1b
considered as significant. and 2b had higher CRPR than Groups 1a and 2a. Tc99m
macroaggregate radioisotopic perfusion scintigram of
two animals from control group (Group 1c) and Group
1b to whom 2 mg VEGF was administrated obtained atResults
40th day were given in Figure 1.
Clinical evaluation
The animals had weakness of the right hind limbs on Angiographic results
The angiographic scores were determined by cal-the first postoperative day. Between 16th day and 25th
days, five animals from Group 1c and 2c, two animals culating the quantitative analysis of developed col-
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Table 2. Angiographic, scintigraphic and histological data of 2 animals from each of the 6 groups – four received VEGF, two served
as controls. Individual values are presented. See Method section for detailed explanation of data.
Group 1 Group 2
(intramuscular group) (intra-arterial group)
Group 1a Group 1b Group 1a Group 1b Group 1a Group 1b
1 mg VEGF 2 mg VEGF 1 mg VEGF 2 mg VEGF 1 mg VEGF 2 mg VEGF
Angiographic score: 26 and 24 33 and 29 10 and 12 27 and 25 28 and 32 12 and 10
(number of collaterals)
Calf radioisotopic 0.58 and 0.52 0.98 and 0.88 0.28 and 0.34 0.53 and 0.45 0.85 and 0.95 0.28 and 0.34
perfusion ratio
Capillary per muscle 0.65 and 0.57 0.84 and 0.76 0.34 and 0.40 0.64 and 0.56 0.72 and 0.78 0.41 and 0.33
fibre ratio
between the groups received the same doses (Groups
1a with 2a and 1b with 2b) of VEGF via the different
routes. These data suggested that the administration
route has no affect (p>0.05), but a dose-response re-
lationship is present (p<0.05).
Discussion
Fig. 2. Digital subtraction angiograms of two rabbits from Group 2c (control) (a) and Group 2b (2 mg VEGF) (b) obtained at 40th day.
The number of new collateral vessels and distal arterial reconstitution in the right hind limb in panel B are evident when compared to
panel A.
lateral vessel in medial thigh. The median number of
vessels crossing the midthigh was 25 in Group 1a, 31
in Group 1b, 11 in Group 1c, 26 in Group 2a, 30 in
Group 2b and 11 in Group 2c (Table 2). Collateral
artery development and distal arterial reconstructions
in midthigh of the animals given VEGF (Groups 1a,
1b, 2a and 2b) were more obvious than that of control
groups (Groups 1c and 2c) (Fig. 2), and also new vessel
formation was better in Groups 1b and 2b from 1a
and 2a.
The experimental model used in the study was de-
signed to simulate the situation found in patients withHistological examination
The results of the cap/mm2 and the cap/f were given critical limb ischaemia. An interval of 10 days between
the first surgical intervention and VEGF administrationin Table 2. Median capillary per muscle fibre ratio was
0.61 in the Group 1a, 0.80 in the Group 1b, 0.37in the was chosen to allow stabilisation of endogenous col-
lateral formation. VEGF and dosing administrationGroup 1c, 0.60 in the Group 2a, 0.75 in the Group 2b
and 0.37 in the Group 2c. were based on the previous studies.10–13
The results of this study suggest that VEGF canIt was seen that new vessel formation was higher
in VEGF administration groups (Groups 1a, 1b, 2a and substantially increase blood flow to an ischaemic limb,
as determined by clinical evaluation: thigh pressure2b) than that in control groups (Groups 1c and 2c)
(p<0.05). In addition, angiogenesis was better in index, calf radioisotopic perfusion ratio, quantitative
angiography, and capillary density and capillary perGroups 1b and 2b than Groups 1a and 2a. However,
a statistically significant difference was not present muscle fibre ratio. Furthermore, there was evidence
Eur J Vasc Endovasc Surg Vol 22, October 2001
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of a dose-response relationship, although the route of With administration of an angiogenic factor to the
ischaemic extremity, Pu et al.11,25 first reported theadministration seemed unimportant.14
The advantage of intra-arterial administration is that formation of successful revascularisation, and they
used basic fibroblast growth factor as angiogenic factor.less is required for the same effect which reduces cost.
By contrast, intramuscular administration does not Bauters13 has observed similar results with IA ad-
ministration of VEGF in ischaemic hind limb model.require insertion of a catheter. Houck’s15 data showed
that more than 50% of exogenous VEGF165 remained Isner et al.26 reported in 6 patients with Buerger’s
disease that therapeutic angiogenesis with plasmidin extracellular space due to proteoglicans attacking
heparin. In collateral development, it has been sug- DNA-encoding VEGF might provide a novel therapy
in patients with advanced thromboangiitis obliteransgested that heparin has a potential stimulatory effect
on endogen basic fibroblast growth factor from extra- that is unresponsive to standard medical or surgical
treatment methods.cellular matrix.10 Soker16 has shown that 2-macro-
globulin (2-M) in circulation binds VEGF with The safety and potential adverse effects of ad-
ministration of such agents must be assessed becausecovalent bond, and as a result VEGF-2-M complex
cannot be bound to VEGF receptors in vascular endo- the animals in the study were not systematically as-
sessed for evidence of haematological, renal or hepaticthelial cells, and so VEGF becomes inactive. If one
gives exogenous heparin, it detaches the VEGF-2-M toxicity after administration of VEGF.
Consequently, in rabbit model of ischaemic hindcomplex. For these reasons, we did use no heparin in
any procedure in our study to avoid any contribution limb, the results from the present study demonstrate
that VEGF accelerates angiogenesis of the ischaemicof heparin on angiogenesis.
The theory of angiogenesis means the formation of rabbit hind limb and administration route has no
affect, but a dose-response relationship is present. Newnew blood vessels.17 Folkman8 and Shweiki18 have
stated basic biologic mechanisms in angiogenesis, and studies performed on human will clarify its effects on
patients with diffuse occlusive vascular disease.have also classified the factors of angiogenesis. Growth
of blood vessels or angiogenesis is necessary for normal
growth and tissue development. It also has a central
role in tissue repair and wound healing. Angiogenesis
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